文献速递血脂与心血管预防心力衰竭与心肌病心律失常

COVID-19的科学基础:对心血管系统的影响

The Science Underlying COVID-19: Implications for the Cardiovascular System.
PubMed 文献 · Circulation · 2020-04-15

该综述阐述了SARS-CoV-2的高感染性与突变及furin切割位点获得相关,无症状者持续排毒加剧传播;病毒经ACE2受体和TMPRSS2蛋白酶内化,组织分布与症状及器官功能障碍相关。病毒诱导ACE2下调可能减弱抗炎作用并增强血管紧张素II效应;早期淋巴细胞减少具预后价值,免疫失衡可致噬血细胞样综合征和多器官衰竭。心血管系统常早期受累,表现为高敏肌钙蛋白和利钠肽释放,炎症可致微血管病伴血栓、心肌炎、心衰、心律失常、急性冠脉综合征和猝死。

要点

  • SARS-CoV-2经ACE2受体和TMPRSS2蛋白酶内化,ACE2下调可能加重血管紧张素II效应。
  • 早期淋巴细胞减少具预后价值,免疫失衡可致噬血细胞样综合征和多器官衰竭。
  • 心血管系统常早期受累,高敏肌钙蛋白和利钠肽持续升高提示预后不良。

核心结论

  • COVID-19通过ACE2受体及免疫失衡机制早期累及心血管系统,高敏肌钙蛋白和利钠肽升高具高度预后价值。
  • 针对心衰、心律失常、急性冠脉综合征和血栓的适当治疗在COVID-19中仍然重要。

研究设计与样本

  • 综述,总结SARS-CoV-2生物学与COVID-19心血管受累机制及临床管理。

主要发现

  • SARS-CoV-2高感染性部分与受体结合域新突变及S-spike蛋白获得furin切割位点相关。
  • 无症状和症状前个体持续病毒排出增强社区传播。
  • 病毒经ACE2受体内化,辅以TMPRSS2蛋白酶。
  • 病毒诱导ACE2下调可能减弱其抗炎作用并增强血管紧张素II效应。
  • 早期淋巴细胞减少具预后价值,可能伴CD4+和部分CD8+T细胞减少。

临床怎么用

  • 基于早期预后指标进行积极支持与期待管理可能改善恢复。
  • 适当治疗心衰、心律失常、急性冠脉综合征和血栓仍然重要。
  • 需抗体检测和有效疫苗以保护更广泛人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The coronavirus disease 2019 (COVID-19) pandemic has affected health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of severe acute respiratory syndrome coronavirus 2 is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S-spike protein. The continued viral shedding in the asymptomatic and presymptomatic individuals enhances its community transmission. The virus uses the angiotensin converting enzyme 2 receptor for internalization, aided by transmembrane protease serine 2 protease. The tissue localization of the receptors correlates with COVID-19 presenting symptoms and organ dysfunction. Virus-induced angiotensin converting enzyme 2 downregulation may attenuate its function, diminish its anti-inflammatory role, and heighten angiotensin II effects in the predisposed patients. Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Appropriate type I interferon pathway activation is critical for virus attenuation and balanced immune response. Persistent immune activation in predisposed patients, such as elderly adults and those with cardiovascular risk, can lead to hemophagocytosis-like syndrome, with uncontrolled amplification of cytokine production, leading to multiorgan failure and death. In addition to the airways and lungs, the cardiovascular system is often involved in COVID-19 early, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all extremely prognostic, in particular, in those showing continued rise, along with cytokines such as interleukin-6. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death. Aggressive support based on early prognostic indicators with expectant management can potentially improve recovery. Appropriate treatment for heart failure, arrhythmias, acute coronary syndrome, and thrombosis remain important. Specific evidence-based treatment strategies for COVID-19 will emerge with ongoing global collaboration on multiple approaches being evaluated. To protect the wider population, antibody testing and effective vaccine will be needed to make COVID-19 history.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Liu PP, Blet A, Smyth D, et al. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020. PMID: 32293910. doi:10.1161/CIRCULATIONAHA.120.047549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。